| Defects in the adherens junction complex (E-cadherin/β-catenin) in inflammatory bowel disease S Mehta, A Nijhuis, T Kumagai, J Lindsay, A Silver Cell and tissue research 360, 749-760, 2015 | 112 | 2015 |
| In Crohn's disease fibrosis-reduced expression of the miR-29 family enhances collagen expression in intestinal fibroblasts A Nijhuis, P Biancheri, A Lewis, CL Bishop, P Giuffrida, C Chan, ... Clinical Science 127 (5), 341-350, 2014 | 98 | 2014 |
| DUOX2 and DUOXA2 Form the Predominant Enzyme System Capable of Producing the Reactive Oxygen Species H2O2 in Active Ulcerative Colitis and are … TS MacFie, R Poulsom, A Parker, G Warnes, T Boitsova, A Nijhuis, ... Inflammatory bowel diseases 20 (3), 514-524, 2014 | 95 | 2014 |
| Role of reactive oxygen species in the abrogation of oxaliplatin activity by cetuximab in colorectal cancer V Santoro, R Jia, H Thompson, A Nijhuis, R Jeffery, K Kiakos, AR Silver, ... Journal of the National Cancer Institute 108 (6), djv394, 2016 | 65 | 2016 |
| Remodelling of microRNAs in colorectal cancer by hypoxia alters metabolism profiles and 5-fluorouracil resistance A Nijhuis, H Thompson, J Adam, A Parker, L Gammon, A Lewis, JG Bundy, ... Human molecular genetics 26 (8), 1552-1564, 2017 | 62 | 2017 |
| Low serum levels of microRNA-19 are associated with a stricturing Crohn's disease phenotype A Lewis, S Mehta, LN Hanna, LA Rogalski, R Jeffery, A Nijhuis, ... Inflammatory Bowel Diseases 21 (8), 1926-1934, 2015 | 58 | 2015 |
| GPER mediates differential effects of estrogen on colon cancer cell proliferation and migration under normoxic and hypoxic conditions V Bustos, ÁM Nolan, A Nijhuis, H Harvey, A Parker, R Poulsom, ... Oncotarget 8 (48), 84258, 2017 | 49 | 2017 |
| RNA‐binding motif protein 39 (RBM39): An emerging cancer target Y Xu, A Nijhuis, HC Keun British Journal of Pharmacology 179 (12), 2795-2812, 2020 | 40 | 2020 |
| Intestinal fibrosis in Crohn's disease: role of microRNAs as fibrogenic modulators, serum biomarkers, and therapeutic targets A Lewis, A Nijhuis, S Mehta, T Kumagai, R Feakins, JO Lindsay, A Silver Inflammatory bowel diseases 21 (5), 1141-1150, 2015 | 36 | 2015 |
| Indisulam targets RNA splicing and metabolism to serve as a novel therapeutic strategy for high-risk neuroblastoma A Nijhuis, A Sikka, O Yogev, L Herendi, C Eckold, G Valbuena, Y Liu, ... Nature Communications, 2022 | 35 | 2022 |
| MCL-1 is modulated in Crohn’s disease fibrosis by miR-29b via IL-6 and IL-8 A Nijhuis, R Curciarello, S Mehta, R Feakins, CL Bishop, JO Lindsay, ... Cell and tissue research 368, 325-335, 2017 | 32 | 2017 |
| Lactic acidosis induces resistance to the pan-Akt inhibitor uprosertib in colon cancer cells EME Barnes, Y Xu, A Benito, L Herendi, AP Siskos, EO Aboagye, ... British Journal of Cancer 122 (9), 1298-1308, 2020 | 27 | 2020 |
| Epithelial down‐regulation of the miR‐200 family in fibrostenosing Crohn's disease is associated with features of epithelial to mesenchymal transition SJ Mehta, A Lewis, A Nijhuis, R Jeffery, P Biancheri, A Di Sabatino, ... Journal of Cellular and Molecular Medicine 22 (11), 5617-5628, 2018 | 23 | 2018 |
| Small-molecule Wnt inhibitors are a potential novel therapy for intestinal fibrosis in Crohns disease A Lewis, S Sánchez, G Berti, B Pan-Castillo, A Nijhuis, S Mehta, L Eleid, ... Clinical Science 136 (19), 1405-1423, 2022 | 11 | 2022 |
| Pharmacological inhibition of the canonical WNT signalling pathway represents a potential novel therapy for fibrosis in Crohn's disease A Lewis, A Nijhuis, G Berti, CL Bishop, R Feakins, JO Lindsay, A Silver | 4 | 2019 |
| Pharmacological depletion of RNA splicing factor RBM39 by indisulam synergizes with PARP inhibitors in high-grade serous ovarian carcinoma Y Xu, S Spear, Y Ma, MP Lorentzen, M Gruet, F McKinney, Y Xu, ... Cell Reports 42 (10), 2023 | 2 | 2023 |
| PWE-255 5-ASA enhances DUOX2 expression in active ulcerative colitis: a risk for colorectal cancer? T Macfie, A Parker, A Nijhuis, T Boitsova, N Suraweera, R Jeffery, ... Gut 61 (Suppl 2), A401-A402, 2012 | 2 | 2012 |
| Abstract B096: Targeting RNA splicing factor RBM39 improves therapy responses in ovarian high-grade serous carcinoma Y Xu, S Spear, Y Ma, M Lorentzen, M Gruet, F McKinney, Y Xu, ... Cancer Research 84 (5_Supplement_2), B096-B096, 2024 | | 2024 |
| Epigenetic and metabolic reprogramming of fibroblasts in Crohn's disease strictures reveals histone deacetylases as therapeutic targets A Lewis, DT Humphreys, B Pan-Castillo, G Berti, C Felice, H Gordon, ... J Crohns Colitis, 2023 | | 2023 |
| RBM39: A druggable metabolic sensor linking RNA splicing, transcriptional regulation, and metabolic reprogramming in cancer HC Keun, A Nijhuis Molecular Cell 83 (23), 4202-4204, 2023 | | 2023 |
Amy LewisQueen Mary's University LondonBestätigte E-Mail-Adresse bei qmul.ac.uk
